Therapies performed for ITP at the time of NGS evaluation
| . | All patients (N = 167) . | NGS pos (n = 31) . | NGS neg (n = 136) . |
|---|---|---|---|
| No. of therapy lines, median (range) | 2 (0-9) | 2 (0-6) | 2 (0-9) |
| Untreated, n (%) | 29 (17%) | 6 (19%) | 23 (17%) |
| 1 line, n (%) | 28 (17%) | 3 (10%) | 25 (18%) |
| 2 lines, n (%) | 46 (28%) | 11 (35.5%) | 35 (26%) |
| ≥3 lines, n (%) | 64 (38%) | 11 (35.5%) | 53 (39%) |
| Corticosteroids, n (%) | 138 (83%) | 25 (81%) | 113 (83%) |
| CR/PR | 64 (46%)/33 (24%) | 9 (36%)/6 (24%) | 55 (49%)/27 (24%) |
| Eltrombopag, n (%) | 75 (45%) | 15 (48%) | 60 (44%) |
| CR/PR | 40 (53%)/15 (20%) | 5 (33%)/5 (33%) | 35 (58%)/10 (17%) |
| Romiplostim, n (%) | 40 (24%) | 9 (29%) | 31 (23%) |
| CR/PR | 19 (48%)/11 (28%) | 3 (33%)/2 (22%) | 16 (52%)/9 (29%) |
| Avatrombopag, n (%) | 14 (8%) | 2 (6%) | 12 (9%) |
| CR/PR | 3 (21%)/0 (0%) | 1 (50%)/0 (0%) | 2 (17%)/0 (0%) |
| Rituximab, n (%) | 39 (23%) | 6 (19%) | 33 (24%) |
| CR/PR | 13 (33%)/7 (18%) | 6 (100%)/0 (0%) | 7 (21%)/7 (21%) |
| Splenectomy, n (%) | 24 (14%) | 3 (10%) | 21 (15%) |
| CR/PR | 9 (38%)/5 (21%) | 0 (0%)/1 (33%) | 9 (43%)/4 (19%) |
| Fostamatinib, n (%) | 22 (13%) | 5 (16%) | 17 (13%) |
| CR/PR | 8 (36%)/2 (9%) | 3 (60%)/1 (20%) | 5 (29%)/1 (6%) |
| Immunosuppressors, n (%) | 38 (23%) | 4 (13%) | 34 (25%) |
| CR/PR | 6 (16%)/10 (26%) | 0 (0%)/0 (0%) | 6 (18%)/10 (29%) |
| IV immunoglobulin, n (%) | 88 (53%) | 20 (6%) | 68 (50%) |
| CR/PR | 40 (45%)/23 (26%) | 7 (35%)/6 (30%) | 33 (49%)/17 (25%) |
| Other therapies, n (%) | 12 (7%) | 3 (10%) | 9 (7%) |
| . | All patients (N = 167) . | NGS pos (n = 31) . | NGS neg (n = 136) . |
|---|---|---|---|
| No. of therapy lines, median (range) | 2 (0-9) | 2 (0-6) | 2 (0-9) |
| Untreated, n (%) | 29 (17%) | 6 (19%) | 23 (17%) |
| 1 line, n (%) | 28 (17%) | 3 (10%) | 25 (18%) |
| 2 lines, n (%) | 46 (28%) | 11 (35.5%) | 35 (26%) |
| ≥3 lines, n (%) | 64 (38%) | 11 (35.5%) | 53 (39%) |
| Corticosteroids, n (%) | 138 (83%) | 25 (81%) | 113 (83%) |
| CR/PR | 64 (46%)/33 (24%) | 9 (36%)/6 (24%) | 55 (49%)/27 (24%) |
| Eltrombopag, n (%) | 75 (45%) | 15 (48%) | 60 (44%) |
| CR/PR | 40 (53%)/15 (20%) | 5 (33%)/5 (33%) | 35 (58%)/10 (17%) |
| Romiplostim, n (%) | 40 (24%) | 9 (29%) | 31 (23%) |
| CR/PR | 19 (48%)/11 (28%) | 3 (33%)/2 (22%) | 16 (52%)/9 (29%) |
| Avatrombopag, n (%) | 14 (8%) | 2 (6%) | 12 (9%) |
| CR/PR | 3 (21%)/0 (0%) | 1 (50%)/0 (0%) | 2 (17%)/0 (0%) |
| Rituximab, n (%) | 39 (23%) | 6 (19%) | 33 (24%) |
| CR/PR | 13 (33%)/7 (18%) | 6 (100%)/0 (0%) | 7 (21%)/7 (21%) |
| Splenectomy, n (%) | 24 (14%) | 3 (10%) | 21 (15%) |
| CR/PR | 9 (38%)/5 (21%) | 0 (0%)/1 (33%) | 9 (43%)/4 (19%) |
| Fostamatinib, n (%) | 22 (13%) | 5 (16%) | 17 (13%) |
| CR/PR | 8 (36%)/2 (9%) | 3 (60%)/1 (20%) | 5 (29%)/1 (6%) |
| Immunosuppressors, n (%) | 38 (23%) | 4 (13%) | 34 (25%) |
| CR/PR | 6 (16%)/10 (26%) | 0 (0%)/0 (0%) | 6 (18%)/10 (29%) |
| IV immunoglobulin, n (%) | 88 (53%) | 20 (6%) | 68 (50%) |
| CR/PR | 40 (45%)/23 (26%) | 7 (35%)/6 (30%) | 33 (49%)/17 (25%) |
| Other therapies, n (%) | 12 (7%) | 3 (10%) | 9 (7%) |
CR, complete response; neg, negative; pos, positive; PR, partial response.